微芯生物与Nizhpharm签署西达本胺许可及分销协议

Group 1 - The core point of the article is that Microchip Biotech (688321.SH) has signed a licensing and distribution agreement with Nizhny Novgorod Chemical Pharmaceutical Plant (Nizhpharm) for the product Chidamide, granting Nizhpharm exclusive rights for research, registration, and commercialization in several countries [1][2] - Nizhpharm will be responsible for the research, market registration, secondary packaging, transportation, and commercialization of Chidamide in the authorized regions [1][2] - The agreement includes an initial payment of 10 million RMB and additional milestone payments totaling 10 million RMB for local registration and market launch [2] Group 2 - Nizhpharm is one of the leading pharmaceutical companies in the Russian Federation, with over a century of history, focusing on unmet medical needs in key therapeutic areas [2] - Chidamide is the world's first subtype-selective histone deacetylase (HDAC) inhibitor, marking a significant milestone for Chinese innovative drugs in licensing out to Europe and the United States [2] - The company will receive a high double-digit percentage of sales revenue based on the net sales achieved in the authorized regions from Nizhpharm [2]